Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
(R)-MG132 and the HNRNPU–PHGDH Evidence
2026-11-18
The cervical-cancer study supports a lactate–HNRNPU K181–PHGDH axis that connects post-translational regulation with serine metabolism and tumor-cell growth. (R)-MG132 has a different interpretive role: as a low-activity MG-132 enantiomeric control for ubiquitin-proteasome system research, it should not be treated as the causal perturbation or validation of the reported lactylation mechanism.
HNRNPU Lactylation and Proteasome-Control Limits
2026-11-18
Evidence from cervical-cancer models links HNRNPU K181 lactylation with PHGDH transcript regulation, serine metabolism and tumor growth. (R)-MG132, the MG-132 enantiomer, belongs to a different evidentiary layer: it is described as a low-activity proteasome-control compound, useful for separating proteasome-dependent effects from pathway-specific claims but not for establishing the HNRNPU mechanism itself.
When Context Changes a Proteasome Result
2026-11-17
A cervical-cancer study connects HNRNPU K181 lactylation with PHGDH regulation and serine metabolism, while (R)-MG132 belongs to a separate proteasome-control context. Reading these results correctly requires distinguishing pathway evidence from comparator logic, downstream readouts, and pharmacological specificity.
When Context Changes a Molecular Result
2026-11-17
The meaning of a molecular result depends on the model, perturbation, comparator, and readout. The cervical-cancer study of HNRNPU K181 lactylation illustrates how protein-level associations, genetic perturbations, and broad pharmacology support different levels of mechanistic inference, while (R)-MG132 belongs to a distinct proteasome-control context rather than serving as direct evidence for this metabolic pathway.
HNRNPU Lactylation Rewires Serine Metabolism
2026-11-16
A 2026 cervical-cancer study links HNRNPU K181 lactylation to PHGDH transcript regulation, serine biosynthesis and tumor growth. The findings support a mechanistic lactate–RNA metabolism axis, while the study’s pharmacological evidence came from pazopanib rather than (R)-MG132. The latter is better interpreted as a low-activity proteasome-control compound, not as evidence for the reported metabolic pathway.
HNRNPU Lactylation Rewires Cervical Cancer Metabolism
2026-11-16
A 2026 study presents HNRNPU lysine 181 lactylation as a metabolic-to-post-transcriptional link that stabilizes PHGDH transcripts, supports serine biosynthesis, and promotes cervical cancer growth. Its genetic evidence is mechanistically informative, while pharmacological interpretation remains limited by the pleiotropic activity of pazopanib and by the study’s model systems.
(R)-MG132 and HNRNPU Lactylation
2026-11-15
A literature-focused analysis of how HNRNPU K181 lactylation was linked to PHGDH regulation, serine metabolism, and cervical-cancer growth—and why (R)-MG132 belongs to proteasome-control interpretation rather than direct validation of that pathway.
When Context Changes a Proteasome Result
2026-11-14
The meaning of a proteasome-associated result depends on the model, assay layer, comparator and causal question. In the cervical-cancer study discussed here, (R)-MG132 is best understood as a stereochemical control for proteasome-dependent effects, while the principal mechanistic evidence concerns HNRNPU K181 lactylation, PHGDH RNA regulation and serine metabolism.
How (R)-MG132 Sharpens Proteasome Causal Inference
2026-11-13
The MG-132 enantiomer (R)-MG132 is most informative as a low-activity proteasome-control compound, not as evidence for the HNRNPU–PHGDH pathway itself. In the cervical-cancer study, genetic perturbations supported a model in which HNRNPU K181 lactylation stabilizes PHGDH-related transcripts and promotes serine-metabolism-dependent growth, while Pazopanib supplied pharmacological evidence with important multi-target limitations.
When Context Changes a Molecular Result
2026-11-13
A molecular result is defined not only by its size or statistical significance, but also by the model, perturbation, comparator and readout that produced it. The reported HNRNPU–PHGDH study illustrates this principle, while (R)-MG132 belongs to a separate proteasome-control framework and should not be treated as evidence for the study’s metabolic mechanism.
(R)-MG132 in the HNRNPU Lactylation Study
2026-11-12
The cited cervical-cancer study proposes that HNRNPU K181 lactylation connects lactate signaling to PHGDH transcript regulation, serine metabolism and tumor growth. (R)-MG132 belongs to a separate proteasome-control framework and should be interpreted as a negative-control material rather than evidence for the proposed metabolic mechanism.
Context Changes What a Cancer Result Means
2026-11-12
The same growth or molecular readout can support different conclusions depending on the model, perturbation, comparator, and measurement. The cervical-cancer study of HNRNPU K181 lactylation illustrates how genetic, molecular, pharmacological, and in vivo evidence converge while still carrying distinct causal limits. The related role of (R)-MG132 shows why a proteasome-control compound should be interpreted as a comparator for target dependence, not as evidence for the lactylation pathway itself.
Phosphorylated H1 at Stressed Replication Forks
2026-11-11
The cited study presents S-phase-phosphorylated linker histone H1 as an organizer of repair factors at collapsed replication forks. Its evidence connects phosphorylation-dependent single-stranded-DNA assembly, HPF1 interaction, cellular damage sensitivity, and fluorescence-based measurement while keeping Cy3 maleimide in a reporting role rather than treating it as the cause of repair.
When Context Changes a Cancer Result
2026-11-11
A cervical cancer study illustrates why molecular, cellular, pharmacological, and control-compound contexts determine what a result can legitimately establish.
When Context Changes a Cancer Result
2026-11-10
A cervical-cancer study illustrates why molecular results cannot be separated from model, perturbation, comparator, and readout. The HNRNPU–PHGDH axis is supported by convergent genetic, molecular, cellular, and animal evidence, while (R)-MG132 belongs to a distinct proteasome-control context rather than serving as evidence for that metabolic mechanism.